Stocks · News reference
Abivax Announces Pricing Of Underwritten Public Offering Of 6.40M ADSs At $125.00 Each
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 1, 2026, 12:40 PM
- Checked
- Jul 1, 2026, 12:45 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Palisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis
Analyst initiates a Buy rating on Palisade Bio with an $8 target, highlighting PALI-2108's multi-billion dollar potential in IBD treatment.
Read original at benzinga'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
https://www.lalettre.fr/fr/english-corner/2026/07/17/biotech-abivax-re-engages-investment-bank-centerview-for-big-pharma-takeover-talks,110842674-gra
Read original at benzingaPiper Sandler Maintains Overweight on Abivax, Raises Price Target to $175
Read original at benzingaAbivax's Phase 3 ABTECT Maintenance Trial Of Obefazimod Met Primary Endpoint Of Clinical Remission And All Key Secondary Endpoints At Week 44 In Ulcerative Colitis
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative ColitisAt Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary
Read original at benzinga